 Myeloid-Lymphoid Leukemia Protein
"Myeloid-Lymphoid Leukemia Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
| Descriptor ID |
D051788
|
| MeSH Number(s) |
D12.776.260.560 D12.776.624.664.700.148 D12.776.930.483
|
| Concept/Terms |
Myeloid-Lymphoid Leukemia Protein- Myeloid-Lymphoid Leukemia Protein
- Myeloid Lymphoid Leukemia Protein
- Zinc Finger Protein HRX
- MLL Proto-Oncogene Protein
- MLL Proto Oncogene Protein
- Proto-Oncogene Protein, MLL
- Proto-Oncogene Proteins MLL
- MLL, Proto-Oncogene Proteins
- Proto Oncogene Proteins MLL
- Acute Lymphoblastic Leukemia Protein 1
- Mixed-Lineage Leukemia Protein
- Mixed Lineage Leukemia Protein
|
Below are MeSH descriptors whose meaning is more general than "Myeloid-Lymphoid Leukemia Protein".
Below are MeSH descriptors whose meaning is more specific than "Myeloid-Lymphoid Leukemia Protein".
This graph shows the total number of publications written about "Myeloid-Lymphoid Leukemia Protein" by people in this website by year, and whether "Myeloid-Lymphoid Leukemia Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 0 | 1 | 1 | | 2009 | 4 | 0 | 4 | | 2010 | 3 | 1 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 0 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 8 | 0 | 8 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 2 | 0 | 2 | | 2021 | 4 | 3 | 7 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloid-Lymphoid Leukemia Protein" by people in Profiles.
-
Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 05 01; 107(5):1205-1208.
-
Liao W, Kohler ME, Fry T, Ernst P. Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia. Exp Hematol. 2021 08; 100:1-11.
-
Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Sci Rep. 2021 06 23; 11(1):13158.
-
Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 05 14; 12(1):2792.
-
Breese EH, Krupski C, Nelson AS, Perentesis JP, Phillips CL. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2021 05 01; 43(4):152-154.
-
Liu X, Zhao Y, Luedke C, Jug R, Yang LH, Lu M, Pan Z, Wang D, Lorsbach R, Shi Y, Knez V, Rehder C, Liang X, Wang E. Infantile leukemia-What factors determine its distinct biological nature? Clinicopathological study of 78 cases. Int J Lab Hematol. 2021 Oct; 43(5):1117-1122.
-
Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
-
Lloyd NR, Wuttke DS. Cyp33 binds AU-rich RNA motifs via an extended interface that competitively disrupts the gene repressive Cyp33-MLL1 interaction in vitro. PLoS One. 2021; 16(2):e0237956.
-
Liu H, Lee S, Zhang Q, Chen Z, Zhang G. The potential underlying mechanism of the leukemia caused by MLL-fusion and potential treatments. Mol Carcinog. 2020 07; 59(7):839-851.
-
Yang W, Trahan GD, Howell ED, Speck NA, Jones KL, Gillen AE, Riemondy K, Hesselberth J, Bryder D, Ernst P. Enhancing Hematopoiesis from Murine Embryonic Stem Cells through MLL1-Induced Activation of a Rac/Rho/Integrin Signaling Axis. Stem Cell Reports. 2020 02 11; 14(2):285-299.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|